scispace - formally typeset
Open AccessJournal ArticleDOI

Evidence against the proposition that "UK cancer survival statistics are misleading": simulation study with National Cancer Registry data.

TLDR
Even implausibly extreme levels of the hypothesised errors in the cancer registry data could not explain the international differences in survival observed between the UK and other European countries.
Abstract
Objectives To simulate each of two hypothesised errors in the National Cancer Registry (recording of the date of recurrence of cancer, instead of the date of diagnosis, for registrations initiated from a death certificate; long term survivors who are never notified to the registry), to estimate their possible effect on relative survival, and to establish whether lower survival in the UK might be due to one or both of these errors. Design Simulation study. Setting National Cancer Registry of England and Wales. Population Patients diagnosed as having breast (women), lung, or colorectal cancer during 1995-2007 in England and Wales, with follow-up to 31 December 2007. Main outcome measure Mean absolute percentage change in one year and five year relative survival associated with each simulated error. Results To explain the differences in one year survival after breast cancer between England and Sweden, under the first hypothesis, date of diagnosis would have to have been incorrectly recorded by an average of more than a year for more than 70% of women known to be dead. Alternatively, under the second hypothesis, failure to register even 40% of long term survivors would explain less than half the difference in one year survival. Results were similar for lung and colorectal cancers. Conclusions Even implausibly extreme levels of the hypothesised errors in the cancer registry data could not explain the international differences in survival observed between the UK and other European countries.

read more

Citations
More filters
Journal ArticleDOI

Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE--5-a population-based study

TL;DR: The major advances in cancer management that occurred up to 2007 seem to have resulted in improved survival in Europe, although results for lung cancer in some regions (central and eastern Europe) might be affected by overestimation.
Journal ArticleDOI

Progress in cancer survival, mortality, and incidence in seven high-income countries 1995–2014 (ICBP SURVMARK-2): a population-based study

TL;DR: Progress in cancer control over the study period was evident for stomach, colon, lung (in males), and ovarian cancer, and the impact of comorbidity are likely the main determinants of patient outcomes.
Journal ArticleDOI

Survival and cure of acute myeloid leukaemia in England, 1971‐2006: a population–based study

TL;DR: The 5‐year relative survival and the percentage ‘cured’ increased for patients aged under 70 years at diagnosis during 1971–2006, but advancing age was associated with poorer outcome, and the long‐term outcome of patients with AML has improved substantially.
References
More filters
Journal ArticleDOI

Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995–99: results of the EUROCARE-4 study

TL;DR: Increases in survival and decreases in geographic differences over time, which are mainly due to improvements in health-care services in countries with poor survival, might indicate better cancer care in wealthy countries with high TNEH.
Book

Survival of cancer patients in Europe: The Eurocare Study

TL;DR: Part 1: Introduction and Methodology F.P. Coleman, C. Cummins, G. Rider, J. Smith and J. Youngson: Health care system, cancer registration and follow-up of cancer patients in the United Kingdom.
Related Papers (5)